Clinical Trials Logo

Postprandial Hypoglycemia clinical trials

View clinical trials related to Postprandial Hypoglycemia.

Filter by:

NCT ID: NCT05676385 Completed - Clinical trials for Postprandial Hypoglycemia

Glucose Response to a Formula for Patients at Risk of Hypoglycaemia

EFFECT
Start date: February 13, 2023
Phase: N/A
Study type: Interventional

This study assesses the glycemic responses to several nutritional products.

NCT ID: NCT05513404 Completed - Clinical trials for Age-Related Memory Disorders

The Scottish Fruit Study

Start date: August 15, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if new varieties of fruits grown in Scotland which can adapt better to climate change namely, honeyberries and cherries, have the same health benefits as established fruits such as raspberries. To do this we will investigate the effects of consuming honeyberries, cherries, and raspberries on short term changes in blood glucose, and on short term memory.

NCT ID: NCT05401578 Recruiting - Clinical trials for Postprandial Hypoglycemia

Canakinumab for the Treatment of Postprandial Hypoglycemia

CanpHy
Start date: April 17, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of this randomized trial is to test whether a treatment with canakinumab is superior to placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it improves health related quality of life (mentally or physically) or reduces the risk of hypoglycemic events.

NCT ID: NCT05174507 Active, not recruiting - Clinical trials for Postprandial Hypoglycemia

Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes

Hypo-PrEA
Start date: June 24, 2022
Phase: Phase 2
Study type: Interventional

This study is to analyze whether the SGLT2-inhibitor empagliflozin or the IL-1 receptor antagonist anakinra may improve postprandial hypoglycemia in subjects with prediabetes.

NCT ID: NCT05036317 Recruiting - Clinical trials for Postprandial Hypoglycemia

Empagliflozin for the Treatment of Postprandial Hypoglycemia

EmpHy
Start date: March 11, 2022
Phase: Phase 3
Study type: Interventional

This randomized trial is to test whether a treatment with empagliflozin is superior to placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it improves health related quality of life (mentally or physically) or reduces the risk of hypoglycemic events.

NCT ID: NCT04836273 Completed - Clinical trials for Postprandial Hypoglycemia

Treatment of Post-bariatric Hypoglycaemia

SHERRY
Start date: August 20, 2021
Phase: Phase 2
Study type: Interventional

This is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, single-centre phase II study aiming to evaluate the efficacy, safety and tolerability of self-administered subcutaneous 120 µg dasiglucagon with an investigational trial device (i.e. a multi-dose reusable pen) for the treatment of postprandial hypoglycaemia after Roux-en-Y gastric bypass (RYGB) surgery. The study is divided into an in-patient and out-patient part. The primary aim of the study is to compare the effects of self-administered 120 µg dasiglucagon versus placebo on continuous glucose monitoring (CGM)-assessed time spent in hypoglycaemia in RYGB-operated individuals in an out-patient setting.

NCT ID: NCT04720859 Recruiting - Clinical trials for Postprandial Hypoglycemia

Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)

CANA-PHH-RYGB
Start date: January 5, 2018
Phase: N/A
Study type: Interventional

Roux-en-Y gastric bypass (RYGB) is the most common surgical procedure for morbid obesity. However, it can present serious late complications, like postprandial hyperinsulinemic hypoglycemia (PHH). Recent data suggested an increase in intestinal SGLT1 after RYGB. However, there are no data on the inhibition of SLGT1 to prevent PHH in patients with prior RYBG. Objectives: To evaluate in patients that present PHH after RYGB: a) the effect of canagliflozin 300mg on the response to 100g glucose overload (OGTT); b) the pancreatic response after intra-arterial calcium stimulation. Material and methods: Prospective pilot study, including patients with PHH after RYGB, matched by age and gender with healthy controls. Basal OGTT and after 2-weeks of daily 300mg of canagliflozin will be performed. In addition, venous sampling after intra-arterial calcium stimulation of the pancreas will be performed.

NCT ID: NCT04330196 Completed - Clinical trials for Roux-en-Y Gastric Bypass

Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance.

DEEP1C
Start date: July 8, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to assess the effect of the natural course of postprandial hypoglycemia vs. a postprandial euglycaemic condition on driving performance in individuals with confirmed postprandial hyperinsulinaemic hypoglycaemia after gastric-bypass surgery.

NCT ID: NCT03984370 Completed - Clinical trials for Postprandial Hypoglycemia

Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass

Start date: September 18, 2019
Phase: Phase 2
Study type: Interventional

The aim of this study is investigating the effect of a novel glucagon analogue administration in gastric bypass operated individuals, who are reactive hypoglycemic.

NCT ID: NCT03200782 Completed - Bariatric Surgery Clinical Trials

Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study

Hypo-BEAR
Start date: May 30, 2017
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate whether hypoglycaemia observed after food intake in bariatric patients can be either influenced by an SGLT2 inhibitor, empagliflozin, or via inhibition of inflammation with an human interleukin-1 receptor antagonist (IL1-RA, anakinra).